Cargando…

Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study

About half of the patients who initiate therapy with mepolizumab discontinue treatment within the first or second year. Concomitant use of short-acting β(2)-agonists and oral corticosteroids drops during mepolizumab use. https://bit.ly/3aRISqS

Detalles Bibliográficos
Autores principales:	Lee, Jason K., Gendron, Alain, Knutson, Michelle, Sriskandarajah, Niroshan, Mbuagbaw, Lawrence, Noorduyn, Stephen G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Original Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005685/ https://www.ncbi.nlm.nih.gov/pubmed/33816603 http://dx.doi.org/10.1183/23120541.00778-2020

Ejemplares similares

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada
por: Sadatsafavi, Mohsen, et al.
Publicado: (2021)

Mepolizumab and COPD in Real Life
por: Revuelta-Salgado, Fernando, et al.
Publicado: (2021)

Incremental healthcare utilisation and costs among new senior high-cost users in Ontario, Canada: a retrospective matched cohort study
por: Muratov, Sergei, et al.
Publicado: (2019)

Trends and determining factors associated with adherence to antiretroviral therapy (ART) in Cameroon: a systematic review and analysis of the CAMPS trial
por: Mbuagbaw, Lawrence, et al.
Publicado: (2012)

SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada)
por: Noorduyn, Stephen G., et al.
Publicado: (2022)

Senior high-cost healthcare users’ resource utilization and outcomes: a protocol of a retrospective matched cohort study in Canada
por: Muratov, Sergei, et al.
Publicado: (2017)

Regional variation in healthcare spending and mortality among senior high-cost healthcare users in Ontario, Canada: a retrospective matched cohort study
por: Muratov, Sergei, et al.
Publicado: (2018)

Severe Pediatric Asthma Therapy: Mepolizumab
por: Ullmann, Nicola, et al.
Publicado: (2022)

Mepolizumab does not alter the blood basophil count in severe asthma
por: Wright, Adam Kelvin Alec, et al.
Publicado: (2019)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

May mepolizumab used in asthma correct subfertility?
por: Ozden, Guzin, et al.
Publicado: (2021)

Mepolizumab in allergic bronchopulmonary aspergillosis complicated by infection
por: Hamada, Toru, et al.
Publicado: (2023)

Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data
por: Husereau, Don, et al.
Publicado: (2018)

Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance
por: Kisling, Adam, et al.
Publicado: (2020)

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines
por: Thommes, Edward W., et al.
Publicado: (2016)

Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada
por: Lee, Jason K, et al.
Publicado: (2020)

Comparison of different medical treatment options for CRSwNP: doxycycline, methylprednisolone, mepolizumab and omalizumab
por: De Schryver, Els, et al.
Publicado: (2015)

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
por: Llanos, Jean-Pierre, et al.
Publicado: (2019)

Outcomes over the first two years of treatment with mepolizumab in severe asthma
por: Elsey, Lynn, et al.
Publicado: (2021)

Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
por: Kay, Dana, et al.
Publicado: (2018)

Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab
por: Herout, Sandra, et al.
Publicado: (2018)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
por: Pradhan, Ravi Ranjan, et al.
Publicado: (2019)

Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
por: Long, Gabriella, et al.
Publicado: (2018)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
por: Mkorombindo, Takudzwa, et al.
Publicado: (2019)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
por: Otoshi, Ryota, et al.
Publicado: (2019)

Characteristics of new adult users of mepolizumab with asthma in the USA
por: Wu, Ann Chen, et al.
Publicado: (2021)

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
por: Pavord, Ian D, et al.
Publicado: (2021)

Daily Physical Activity in Asthma and the Effect of Mepolizumab Therapy
por: Panagiotou, Marios, et al.
Publicado: (2022)

Mepolizumab induced palmoplantar psoriasis: A case report
por: Artosi, Fabio, et al.
Publicado: (2023)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
por: Gibson, Peter G., et al.
Publicado: (2021)

Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
por: Pini, Laura, et al.
Publicado: (2021)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
por: Ueno, Masanobu, et al.
Publicado: (2022)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab
por: Terashima, Takeshi, et al.
Publicado: (2018)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
por: Condreay, Lynn D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i4c65aau3nnlejujk7tuq1i0ah